The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

09-03-2023

Sarah Speight

The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn

Valeriya Zankovych / Shutterstock.com

The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.

Big pharma is no stranger to controversy, and AbbVie is perhaps one of the most lambasted.

Much criticism has been levelled against the firm for what is deemed to be an aggressive global patent strategy regarding its blockbuster drug Humira.

Humira is the brand name of the original adalimumab, an anti-inflammatory drug used to treat eleven conditions, including arthritis, psoriasis, Crohn's Disease and Spondylitis.


AbbVie, Humira, Pharmaceutical Accountability Foundation, patents, biosimilars, adalimumab

LSIPR